| Literature DB >> 29719628 |
Elena I Fedoros1,2, Alexey A Orlov3, Alexander Zherebker3,4, Ekaterina A Gubareva1, Mikhail A Maydin1, Andrey I Konstantinov3, Konstantin A Krasnov5, Ruben N Karapetian6, Ekaterina I Izotova2, Sergey E Pigarev2, Andrey V Panchenko1, Margarita L Tyndyk1, Dmitry I Osolodkin7,8, Evgeny N Nikolaev4,9,10, Irina V Perminova3, Vladimir N Anisimov1.
Abstract
Identification of molecular targets and mechanism of action is always a challenge, in particular - for natural compounds due to inherent chemical complexity. BP-Cx-1 is a water-soluble modification of hydrolyzed lignin used as the platform for a portfolio of innovative pharmacological products aimed for therapy and supportive care of oncological patients. The present study describes a new approach, which combines in vitro screening of potential molecular targets for BP-Cx-1 using Diversity Profile - P9 panel by Eurofins Cerep (France) with a search of possible active components in silico in ChEMBL - manually curated chemical database of bioactive molecules with drug-like properties. The results of diversity assay demonstrate that BP-Cx-1 has multiple biological effects on neurotransmitters receptors, ligand-gated ion channels and transporters. Of particular importance is that the major part of identified molecular targets are involved in modulation of inflammation and immune response and might be related to tumorigenesis. Characterization of molecular composition of BP-Cx-1 with Fourier Transform Ion Cyclotron Resonance Mass Spectrometry and subsequent identification of possible active components by searching for molecular matches in silico in ChEMBL indicated polyphenolic components, nominally, flavonoids, sapogenins, phenanthrenes, as the major carriers of biological activity of BP-Cx-1. In vitro and in silico target screening yielded overlapping lists of proteins: adenosine receptors, dopamine receptor DRD4, glucocorticoid receptor, serotonin receptor 5-HT1, prostaglandin receptors, muscarinic cholinergic receptor, GABAA receptor. The pleiotropic molecular activities of polyphenolic components are beneficial in treatment of multifactorial disorders such as diseases associated with chronic inflammation and cancer.Entities:
Keywords: BP-Cx-1; ChEMBL; cancer; molecular targets; polyphenols
Year: 2018 PMID: 29719628 PMCID: PMC5915095 DOI: 10.18632/oncotarget.24990
Source DB: PubMed Journal: Oncotarget ISSN: 1949-2553
Structural group composition of BP-Cx-1 as measured by 13C and 1H NMR spectroscopy
| Carbon content in the structural fragments,% | ||||||
|---|---|---|---|---|---|---|
| O = | CAr-O(H,R) | CAr | CAlk-O | OCH3 | CAlk | |
| 4 | 6 | 8 | 45 | 15 | 7 | 15 |
| COOH+ArOH | ArH | C | AlkH | |||
| 6.8 | 36 | 34.5 | 19.7 | |||
Figure 1ESI FTICR mass-spectrum of the lignin derivative used in this study - BP-Cx-1
Insert shows the presence of singly and doubly charged ions within 0.25 Da of mass-spectrum fragment.
Figure 2Visualization of FTICR MS data obtained for the BP-Cx-1 lignin derivative: (A) Van Krevelen diagram, (B) H/C versus molecular weight diagram. The molecular compositions of singly and doubly charged ions are highlighted in blue and red colors, respectively.
Binding targets of BP-Cx-1 identified by Diversity Profile–P9 panel
| Receptor family | Target | Protein/protein family symbol | Inhibition% |
|---|---|---|---|
| Adenosine receptors | A1 (h) | ADORA1 | 62.1% |
| A2A (h) | ADORA2A | 86.6% | |
| Adrenergic receptors | α2 | ADRA2A-C | 52.2% |
| β1 (h) | ADRB1 | 51.5% | |
| β2 (h) | ADRB2 | 71.4% | |
| GABAA (γ-Aminobutyric acid) | BZD | GABRA1 | 53.8% |
| Glutamate | AMPA | GRIA 1-4 | 90.9% |
| Kainate | GRIK 1-5 | 84.3% | |
| Bradykinin receptors | B1 (h) | BDKRB1 | 76.7% |
| Dopamine receptors | D4.4 (h) | DRD4 | 62.7% |
| Histamine receptors | H1 (h) | HRH1 | 57.6% |
| Cholinergic receptors | α4β2 (h) | CHRNB2, CHRNA4 | 73.5% |
| M | CHRM1-5 | 96.3% | |
| Vasopressin receptor | V2 (h) | AVPR2 | 69.8% |
| V1a (h) | AVPR1A | 56.4% | |
| Ion channels | KATP | KCNJ | 50.3% |
| Transporters | GABA | SLC6A1 | 71.5% |
| Thyroid Stimulating Hormone receptor | TRH1 (h) | TSHR | 68.8% |
| Glucocorticoid receptor | GR (h) | NR3C1 | 63.2% |
| Serotonin receptor | 5-HT1 | HTR1 A,B,D,E,F | 81% |
| Purinergic receptors | P2X | P2RX1-7 | 64% |
| P2Y | P2RY1,2,4,6,11–14 | 52.6% | |
| Prostanoid receptors | EP2 (h) | PTGER2 | 52.4% |
| IP (PGI2) | PTGIR | 68.7% |
Figure 3Examples of Boolean bioactivity fingerprints
Figure 4STRING protein association network for BP-Cx-1 and ChEMBL compounds targets
Bright-green–targets: activity of the well-fitted ChEMBL compound matched activity of BP-Cx-1; Light-green–targets: activity of other ChEMBL compounds matched activity of BP-Cx-1; Yellow–targets: activity of the well-fitted ChEMBL compound did not match activity of BP-Cx-1 (binding by BP-Cx-1 below 50%); Blue–targets: activity of other ChEMBL compounds did not match activity of BP-Cx-1 (binding by BP-Cx-1 below 50%); Red–BP-Cx-1 targets: no matching activity records were identified in the ChEMBL database.
Figure 5Visualization of derived molecular space (A) Van Krevelen and (B) H/C versus molecular weight diagram. Blue, orange and green spheres represent formulas for FTICR MS compounds, ChEMBL compounds and ChEMBL well-fitted compounds, respectively.
Murcko scaffolds distribution for all ChEMBL compounds and ChEMBL compounds with fit_score ≥1 (well fitted to BP-Cx-1 bioactivity)
| Well fitted ChEMBL compounds | All ChEMBL compounds | ||||
|---|---|---|---|---|---|
| # | Scaffold | % | # | Scaffold | % |
| 1A | 11.1 | 1B | 6.3 | ||
| 2A | 4.5 | 2B | 5.6 | ||
| 3A | 3.7 | 3B | 3.3 | ||
| 4A | 3.1 | 4B | 3.0 | ||
| 5A | 2.8 | 5B | 2.2 | ||